




RealRate

PHARMACEUTICAL 2022

NEXIEN BIOPHARMA INC.
Rank 475 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

NEXIEN BIOPHARMA INC. Rank 475 of 475

The relative strengths and weaknesses of NEXIEN BIOPHARMA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NEXIEN BIOPHARMA INC. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 5,629% points. The greatest weakness of NEXIEN BIOPHARMA INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 22,622% points.

The company's Economic Capital Ratio, given in the ranking table, is -23,333%, being 23,056% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	26
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	39
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,844
Other Liabilities	0
Other Net Income	-16
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	26
Liabilities	39
Expenses	1,844
Stockholders Equity	-14
Net Income	-1,860
Comprehensive Net Income	-1,860
Economic Capital Ratio	-23,333%

